l-nmma
Small moleculeexperimental
Clinical trial activity
39 trials · 35 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
8
Phase 3
1
Phase 4
3
Earliest trial started Feb 1, 2000 (NCT00004575)
Timeline
Indications
Approved for
Studied for
- Anemia · Phase 2
- Anemia, Sickle Cell · Phase 2
- Anthracyclines · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Cerebral Arterial Diseases · Early Phase 1
- Diabetes Mellitus, Type 2 · Phase 4
- DNA Repair-Deficiency Disorders · Phase 1
- Endothelium-Dependent Relaxing Factors · Phase 2
- Endotoxemia · Phase 1
- Fatigue Syndrome, Chronic · Phase 1
- Healthy Volunteers · Phase 4
- Heart Failure · Phase 1
- HIV · Phase 1
- Hodgkin Disease · Phase 1
- Hypercapnia · Phase 1
- Hyperlipidemias · Phase 2/Phase 3
- Hypertension · Phase 1
- Hypertension, Pulmonary · Phase 1
- Hypotension, Orthostatic · Phase 2
- Hypoxia · Phase 1
- Intestinal Neoplasms · Phase 1
- Melanoma · Phase 1
- Metabolic Syndrome · Phase 1
- Nitric Oxide · Phase 2
- Obesity · Phase 4
- Orthostatic Intolerance · Phase 1
- Postural Orthostatic Tachycardia Syndrome · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 1
- Saliva · Phase 1
- Sarcopenia · Phase 1
- Sleep Apnea, Obstructive · Phase 4
- Spinal Cord Injuries · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Syncope, Vasovagal · Early Phase 1
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- Nitric-oxide synthase, brainINHIBITOR
NOS1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- l - nmma
- l - nmma
- l-nmma
- l-nmma
- l-nmma
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05660083 | Phase 2 | Jan 1, 2023 | Methodist Cancer Center, Houston, Texas, Novartis, The University of Texas, Dallas |
| NCT03066115 | Phase 1 | Dec 1, 2020 | University of Wisconsin |
| NCT04265053 | Early Phase 1 (Phase 1) | May 31, 2020 | University of Wisconsin |
| NCT04095689 | Phase 2 | Jan 31, 2020 | Merck, Methodist Cancer Center, Houston, Texas |
| NCT03446612 | Phase 2 | Oct 15, 2018 | GlaxoSmithKline |
| NCT03236935 | Phase 1 | Feb 1, 2018 | Methodist Cancer Center, Houston, Texas |
| NCT03534661 | Phase 2/Phase 3 (Phase 3) | Sep 27, 2017 | University of Toronto |
| NCT02936687 | Phase 1 | Jan 31, 2017 | University of Wisconsin |
| NCT02834403 | Phase 1 | Jul 1, 2016 | Methodist Cancer Center, Houston, Texas, The Methodist Hospital System |
| NCT02183779 | N/A | Jun 1, 2014 | University of Grenoble |
| NCT02245165 | Phase 1 | Jun 1, 2013 | Bengt Ihre Foundation, The Swedish Society of Medicine, Uppsala University |
| NCT01744236 | Phase 4 | Apr 1, 2013 | Free University of Amsterdam, University of Amsterdam |
| NCT01791816 | Early Phase 1 (Phase 1) | Feb 1, 2013 | New York Medical College |
| NCT01701973 | Phase 4 | Jan 1, 2013 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Vanderbilt University |
| NCT01689090 | N/A | Nov 30, 2012 | Aarhus University |
| NCT01290198 | N/A | Feb 1, 2011 | University of Grenoble |
| NCT01398943 | N/A | Sep 1, 2010 | American Heart Association, Augusta University |
| NCT00835224 | Phase 2 | May 1, 2010 | Department of Veteran Affairs |
| NCT01060930 | N/A | Mar 1, 2010 | NHS Lothian, Umea University, University of Edinburgh |
| NCT01122407 | Phase 1 | Jan 1, 2010 | National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University |
Showing 20 of 39 trials
Page 1 / 2
Organizations
Research & Development (35)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 9 | 5 | 4 | 2000 |
| National Institutes of Health (NIH) | Government | 6 | 3 | 4 | 2001 |
| Vanderbilt University | Academic/Hospital | 5 | 5 | 3 | 2002 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 4 | 2 | 2 | 2016 |
| University of Wisconsin | Academic/Hospital | 3 | 3 | 1 | 2017 |
| Aarhus University | Academic/Hospital | 2 | 2 | 2 | 2005 |
| Department of Veteran Affairs | Government | 2 | 1 | 2 | 2008 |
| National Institute on Aging (NIA) | Government | 2 | 0 | 2 | 2005 |
| University of Grenoble | Academic/Hospital | 2 | 2 | 1 | 2011 |
| American Heart Association | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Augusta University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Bengt Ihre Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2013 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2018 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Merck | For profit | 1 | 0 | 1 | 2020 |
| National Center for Research Resources (NCRR) | Government | 1 | 0 | 1 | 2007 |
| New York Medical College | Academic/Hospital | 1 | 1 | 1 | 2013 |
| NHS Lothian | Academic/Hospital | 1 | 0 | 1 | 2010 |
35 organizations
Page 1 / 2